Bastiano Sanna - Feb 10, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 10, 2023
Transactions value $
-$1,593,878
Form type
4
Date filed
2/14/2023, 04:08 PM
Previous filing
Feb 3, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$265K -902 -1.34% $294.33 66.4K Feb 10, 2023 Direct
transaction VRTX Common Stock Tax liability -$1.29M -4.34K -6.54% $298.26 62K Feb 13, 2023 Direct
transaction VRTX Common Stock Sale -$33.9K -113 -0.18% $300.39 61.9K Feb 13, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.39 (range $300.00 to $300.79).